Jeff Wren - UCB SA Insider

UCBJY -- USA Stock  

USD 40.23  1.83  4.77%

Executive Vice President Neurology ? Patient Value Unit Head
Mr. Jeff Wren has served as Executive Vice President, Neurology Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 2015. He joined the Company in October 2010. In his current role, he heads UCBs neurology patient value unit, neurology being one of UCBs two main therapy areas. He is responsible for the entire value chain of UCBs neurology portfolio, from development through medical, market access, sales and marketing. Before taking on his current role he was Senior Vice President UCB North America. He was responsible for providing leadership and strategic direction to all aspects of the organizations operations in both the US and Canada. Prior to this he was Vice President of UCBs Managed Markets and Trade Relations in the US and head of UCBs Canada operations. He has served as the Chairman of the Board for UCB, Inc. in the US as well as UCB Canada. He was member of the board of directors for BIO International, as well as Vicechair and executive committee member for Georgia Bio association group. He was member of the board of advisors for the Metro Atlanta Chamber of Commerce. He holds BS in Biology from Missouri Southern State University, Joplin, Missouri. At INSEAD he also completed Executive Business Program.
Age: 54  President Since 2015      
32 2 559 99 99  http://www.ucb.com

Management Efficiency

The company has return on total asset (ROA) of 6.67 % which means that it generated profit of $6.67 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.73 % meaning that it generated $13.73 on every $100 dollars invested by stockholders.
The company has accumulated 1.83 B in total debt with debt to equity ratio (D/E) of 27.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.34 which is within standard range for the sector.

Similar Executives

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7478 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,478 people.

UCB SA Leadership Team

Pascale Richetta, President
Detlef Thielgen, CFO
Kay Davies, Director
Dirk Teuwen, VP
Anna Richo, EVP
Viviane Monges, Director
Gerhard Mayr, Chairman
Cyril Janssen, Director
Cedric Rijckevorsel, Director, CFA
JeanChristophe Tellier, Chairman
Arnoud Calesberg, Director
Mark McDade, COO
Xavier Michel, President
Dhavalkumar Patel, President
Bharat Tewarie, President, MBA
Roch Doliveux, Chairman
Norman Ornstein, Director
Jeff Wren, President
JeanPierre Kinet, Director, Ph.D
Antje Witte, VP
Alice Dautry, Director
Harriet Edelman, Director, MBA
Ulf Wiinberg, Director
Thomas McKillop, Director, Ph.D
Charl Zyl, President
France Nivelle, VP
Fabrice Enderlin, President
Pierre Gurdjian, Director
Ismail Kola, EVP, Ph.D
Emmanuel Caeymaex, President
Evelyn Bergendal, Executive
Iris LoewFriedrich, President, Ph.D
CharlesAntoine Janssen, Director
Albrecht Graeve, Director
JeanLuc Fleurial, President
Alexander Moscho, President

Stock Performance Indicators

Did you try this?

Run Equity Search Now
   

Equity Search

Search for activelly-traded equities including funds and ETFs from over 30 global markets
All  Next Launch Equity Search

Also Currentnly Active

Purchased over 30 shares of
1 hour ago
Traded for 83.93
Purchased over 500 shares of
1 hour ago
Traded for 5.66
Purchased over 40 shares of
1 hour ago
Traded for 67.0
Also please take a look at World Market Map. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.